Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS adolescent vaccination “hot buttons”

Executive Summary

The HHS National Vaccines Advisory Committee's adolescent working group identifies three "hot button" issues concerning adolescent immunization: school mandates for vaccination, informed consent and use of non-traditional venues for adolescent immunization. The group hopes to publish a draft "defining the problems" in the upcoming months and put out a report within a year. A number of adolescent vaccines have been approved recently, including Merck's human papillomavirus vaccine Gardasil and Sanofi-Pasteur's meningococcal conjugate vaccine Menactra (1"The Pink Sheet" Feb. 28, 2005, p. 28)...

You may also be interested in...

Menactra Launches For 11, 12, 15 Year Olds; First In Wave Of Teen Vaccines?

Sanofi-Pasteur will have approximately 5 mil. doses of Menactra (meningococcal quadrivalent conjugate vaccine) available for use in the U.S. during the first 12 months following launch

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts